Expanding into global markets
First written in FY2016-Q3. 22 of 30 entries say "Restated". Latest entry: 2026-05-11.
The whole theme swung hardest in 2023: 2 of 18 companies on the "Worse" side.
2 other companies' latest entry also says "First stated".
- FY2024-Q1RestatedAnnual report
「With a sense of urgency, the entire Group is pursuing its growth strategy toward 2030 by advancing its businesses in the ASEAN and North American markets and enhancing the pipeline of new drugs, biosimilars and generics so that it can expand further over the following 5 years.」
The company continues its business expansion in the ASEAN and North American markets and its growth strategy toward 2030, looking ahead to further expansion thereafter. - FY2023-Q3RestatedAnnual report
「With a sense of urgency, the entire Group is pursuing its growth strategy toward 2030 by actively entering overseas businesses such as ASEAN and North America and enhancing the pipeline of new drugs, biosimilars and generics so that it can expand further over the following 5 years.」
The company continues its policy of entering overseas businesses in ASEAN and North America and expanding the pipeline in anticipation of further expansion thereafter. - FY2023-Q2RestatedAnnual report
「With a sense of urgency, the entire Group is pursuing its growth strategy toward 2030 by actively entering overseas businesses such as ASEAN and North America and enhancing the pipeline of new drugs, biosimilars and generics so that it can expand further over the following 5 years.」
The company continues its policy of entering overseas businesses in ASEAN and North America and expanding the pipeline in anticipation of further expansion thereafter. - FY2023-Q1RestatedAnnual report
「With a sense of urgency, the entire Group is pursuing its growth strategy toward 2030 by actively entering overseas businesses such as ASEAN and North America and enhancing the pipeline of new drugs, biosimilars and generics so that it can expand further over the following 5 years.」
The company continues its entry into overseas businesses in ASEAN and North America and its growth strategy, looking ahead to further expansion thereafter. - FY2022RestatedAnnual report
「With a sense of urgency, the entire Group is pursuing its growth strategy toward 2030 by actively entering overseas businesses such as ASEAN and North America and enhancing the pipeline of new drugs, biosimilars and generics so that it can expand further over the following 5 years.」
The company continues its entry into overseas businesses in ASEAN and North America and its growth strategy toward 2030. - FY2022-Q3RestatedAnnual report
「With a sense of urgency, the entire Group is pursuing its growth strategy toward 2030 by actively entering overseas businesses such as ASEAN and North America and enhancing the pipeline of new drugs, biosimilars and generics so that it can expand further over the following 5 years.」
The company continues to document entry into overseas businesses in ASEAN and North America and its growth strategy toward 2030. - FY2022-Q2RestatedAnnual report
「With a sense of urgency, the entire Group is pursuing its growth strategy toward 2030 by actively entering overseas businesses such as ASEAN and North America and enhancing the pipeline of new drugs, biosimilars and generics so that it can expand further over the following 5 years.」
The company continues its entry into overseas businesses in ASEAN and North America and its growth strategy toward 2030. - FY2022-Q1RestatedAnnual report
「Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」
The company continues to document entry into overseas businesses in ASEAN and North America and its growth strategy toward 2030. - FY2021RestatedAnnual report
「With a sense of urgency, the entire Group is pursuing its growth strategy toward 2030 by actively entering overseas businesses such as ASEAN and North America and enhancing the pipeline of new drugs, biosimilars and generics so that it can expand further over the following 5 years.」
The company continues to document entry into overseas businesses in ASEAN and North America and its growth strategy toward 2030. - FY2021-Q3RestatedAnnual report
「With a sense of urgency, the entire Group is pursuing its growth strategy toward 2030 by actively entering overseas businesses such as ASEAN and North America and enhancing the pipeline of new drugs, biosimilars and generics so that it can expand further over the following 5 years.」
The company continues to document entry into overseas businesses in ASEAN and North America and its growth strategy toward 2030. - FY2021-Q2RestatedAnnual report
「With a sense of urgency, the entire Group is pursuing its growth strategy toward 2030 by actively entering overseas businesses such as ASEAN and North America and enhancing the pipeline of new drugs, biosimilars and generics so that it can expand further over the following 5 years.」
The company continues to document entry into overseas businesses in ASEAN and North America and its growth strategy toward 2030. - FY2021-Q1RestatedAnnual report
「With a sense of urgency, the entire Group is pursuing its growth strategy toward 2030 by actively entering overseas businesses such as ASEAN and North America and enhancing the pipeline of new drugs, biosimilars and generics so that it can expand further over the following 5 years.」
The company continues to document entry into overseas businesses in ASEAN and North America and its growth strategy toward 2030. - FY2020RaisedAnnual report
「With “Making ‘Fuji-like’ new” as the theme of this medium-term management plan, the entire Group is pursuing its growth strategy toward 2030 by strengthening its core areas of women’s healthcare and acute care, actively and rapidly entering overseas businesses such as ASEAN and North America, and enhancing the pipeline of new drugs, biosimilars and generics so that it can expand further over the following 5 years.」
The scope of the target regions and initiatives has expanded from the former overseas market expansion to active entry into ASEAN and North America, pipeline expansion and alignment with the 2030 vision. - FY2020-Q2RestatedAnnual report
「Under these circumstances, the Group has newly adopted the following as its 2030 vision: “Contributing to improving the well-being of women worldwide,” “Expanding from Toyama, the home of pharmaceuticals, into the Global Market,” and “Integrating the world’s happiest company with contributions to society.” The entire Group is working on its growth strategy toward 2030.」
The company continues to document its efforts under the 2030 vision and growth strategy, including expansion into global markets. - FY2020-Q1ReframedAnnual report
「Under these circumstances, the Group has newly adopted the following as its 2030 vision: “Contributing to the well-being of women worldwide,” “Expanding from Toyama, the home of pharmaceuticals, into the Global Market,” and “Integrating the world’s happiest company with contributions to society.” The entire Group is working on its growth strategy toward 2030.」
Global market expansion has been reorganized from the former challenges of establishing the management foundation and strengthening the overseas business as a component of the 2030 vision. - FY2019AdvancedAnnual report
「As a result, we achieved a measure of progress, including the development of branded drugs through in-licensing from European companies Mithra and Besins Healthcare, and the expansion of the business of our subsidiary OLIC (Thailand) Limited.」
Regarding the strengthening of its overseas business, the company identifies progress in developing branded drugs through in-licensing from European companies and expanding OLIC’s business. - FY2019-Q3RestatedAnnual report
「Establishing the management foundation for expansion into global markets」
The company continues to regard expansion into global markets and the establishment of the management foundation required for it as urgent management priorities. - FY2019-Q2RestatedAnnual report
「Establishing the management foundation for expansion into global markets」
The company continues to regard expansion into global markets and the establishment of the management foundation required for it as urgent management priorities. - FY2019-Q1RestatedAnnual report
「Establishing the management foundation for expansion into global markets」
The company continues to regard global market expansion and the establishment of the management foundation required for it as urgent management priorities. - FY2018AdvancedAnnual report
「We will further promote expansion into overseas markets, using the Toyama Plant and OLIC as starting points and basing our strategy on alliances with pharmaceutical companies in Japan and overseas. We will expand our global CMO business through OLIC’s injectable drug manufacturing facility, which began operations in January 2018, and aim to become a “Sustainable Leading CMO in APAC.”」
Regarding expansion into overseas markets, the company documents a policy centered on alliances among the Toyama Plant, OLIC and pharmaceutical companies in Japan and overseas, as well as the start of operations at OLIC’s injectable drug manufacturing facility in January 2018. - FY2018-Q3RestatedAnnual report
「Establishing the management foundation for expansion into global markets」
The company continues to regard expansion into global markets and the establishment of the management foundation required for it as urgent management priorities. - FY2018-Q2RestatedAnnual report
「Establishing the management foundation for expansion into global markets」
The company continues to regard expansion into global markets and the establishment of the management foundation required for it as urgent management priorities. - FY2018-Q1RestatedAnnual report
「Establishing the management foundation for expansion into global markets」
The company continues to regard establishing the management foundation for global market expansion as an urgent management priority. - FY2017RaisedAnnual report
「We will further promote expansion into overseas markets, using the Toyama Plant and OLIC as starting points and basing our strategy on alliances with pharmaceutical companies in Japan and overseas.」
The scope of the discussion has expanded from establishing the management foundation for global market expansion to realizing overseas expansion centered on alliances among the Toyama Plant, OLIC and pharmaceutical companies in Japan and overseas. - FY2017-Q3RestatedAnnual report
「Establishing the management foundation for expansion into global markets」
The company continues to identify expansion into global markets and the establishment of the management foundation required for it as challenges. - FY2017-Q2RestatedAnnual report
「Establishing the management foundation for expansion into global markets」
The company continues to identify expansion into global markets and the establishment of the management foundation required for it as challenges. - FY2017-Q1RestatedAnnual report
「Establishing the management foundation for expansion into global markets」
The company continues to identify expansion into global markets and the establishment of the management foundation required for it as challenges. - FY2016-Q3First statedAnnual report
「Expanding into global markets」
Expansion into overseas markets is explicitly identified as one of the urgent management priorities.